Antibiogram of Pseudomonas aeruginosa Clinical Isolates Tested for Pan, Extensive and Multidrug Resistances

Uzoamaka Maduakor

Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Nigeria, Nigeria.

Clara Eleazar *

Departments of Microbiology, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria.

Chidozie Nwafor

Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Nigeria, Nigeria.

Veronica Emenuga

Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Nigeria, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Background: Pseudomonas aeruginosa usually cause nosocomial infections with concurrent morbidity and mortality and is generally resistant to many antibiotics.

Aim: This study was aimed to determine the proportion of pan-drug-resistant (PDR), extensively drug-resistant (XDR), and multidrug-resistant (MDR) P. aeruginosa strains recovered from human samples.

Methodology: The retrospective study was conducted in the University of Nigeria Teaching Hospital Enugu in 2023. Clinical samples obtained from patients between October 2022 and April 2023 were analysed. A total of 100 Pseudomonas aeruginosa isolates recovered from 780 clinical samples were used. Standard microbiological techniques were used to identify and categorize the isolates. Antibiotic susceptibility pattern was determined using the Kirby Bauer disc diffusion method.

Results:  Isolates recovered from wound was 38%, voided urine, catheter tip urine, ear swab, and high vaginal swab samples recorded 29%, 11%, 10% and 4%, respectively. Ceftazidime recorded the highest level of resistance (70.0%) and the least was Colistin (20%). Resistance patterns showed that 32(32.0%) bacterial strains were MDR,   68(68.0%) were XDR and no PDR was recorded.

Conclusions: For the best selection of empirical therapy, P. aeruginosa susceptibility monitoring is essential due to the high prevalence of antibiotic resistance. The resistance pattern raises the possibility of misuse of broad-spectrum antibiotics. Treatment for bacterial infections should be directed by the results of antimicrobial susceptibility tests.

Keywords: Pseudomonas aeruginosa, antibiotic, nosocomial, resistance, infections


How to Cite

Maduakor , U., Eleazar , C., Nwafor , C., & Emenuga , V. (2023). Antibiogram of Pseudomonas aeruginosa Clinical Isolates Tested for Pan, Extensive and Multidrug Resistances. Microbiology Research Journal International, 33(11), 14–21. https://doi.org/10.9734/mrji/2023/v33i11-121413

Downloads

Download data is not yet available.

References

Addis T, Araya S, Desta K. Occurrence of Multiple, Extensive and Pan Drug-Resistant Pseudomonas aeruginosa and Carbapenemase Production from Presumptive Isolates Stored in a Biobank at Ethiopian Public Health Institute. Infection and Drug Resistance. 2021; 14:3609-3618.

Karami P, Mohajeri P, Mashouf RY. et al Molecular characterization of clinical and environmental Pseudomonas aeruginosa isolated in burn center. Saudi J. Biol Sci. 2019;26(7):1731-1736. DOI: 10.1016/jsjbs.2018.07.009.

Pang Z, Raudonis R, Glick BR, Lin T, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnology Advances. 2019;37(1):177-192. DOI:org/10.1016/j.biotechadv.2018.11.013

El Solh AA, Alhajhusain A. Update on treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemther. 2009; 64(2):229-38. DOI:10.1083/jac/dkp201.

Park SY, Park HJ, Moon SM, Park KH, Chong YP et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis. 2012;12:308

Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582–610.

World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed (2017) (accessed 17 Sep 2021). Avalable:https://www.who.int>News>item

Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10:441–451.

Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Update. 2000;3:247–255.

Breidenstein EB, De la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19:419–426.

Drenkard E, Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect. 2003;5:1213–1219.

Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010;192:6191– 6199.

Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control. 2006;34(5):10.

Strateva T, Yordanov D. Pseudomonas aeruginosa a phenomenon of bacteria resistance. J Med Microb. 2009;58:1133-48.

Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.

Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619-29.

Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25(10): 1353-64.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18 (3):268-81.

Cheesbrough M (ed). Pseudomonas and related organisms; Biochemical test to identify bacteria; Antimicrobial susceptibility testing. In: District Laboratory Practice in Tropical Countries Part II. Low price edition 2000. Cambridge University Press, Cambridge. 2000;193–194:63–70:132–143.

CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100–S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.

Isichei-Ukah OB, Enabulele, OI. Prevalence and antimicrobial resistance of pseudomonas aeruginosa recovered from environmental and clinical sources in benin city. Ife Journal of Science. 2018;20(3):1734-1738.

Davane M, Suryawanshi N, Pichare A, Nagoba BS. Pseudomonas aeruginosa from hospital environment. J Microbiol Infect Dis. 2014;4:01. DOI:10.5799/ahinjs.02.2014.01.0124

Kateete DP, Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007–2009). Springerplus. 2016;5(1): 1–11. DOI:10.1186/s40064- 016-2986-7

Uc-Cachón AH, Gracida-Osorno C, Luna-Chi IG, Jiménez- Guillermo JG, Molina-Salinas GM. High prevalence of antimicrobial resistance among gram-negative isolated Bacilli in intensive care units at a tertiary-care hospital in Yucatan Mexico. Medicina. 2019;55(9):588. DOI:10.3390/medicina55090588

Kumari M, Khurana S, Bhardwaj N, Malhotra R, Mathur P. Pathogen burden & associated antibiogram of Pseudomonas spp. in a tertiary care hospital of India. Indian J Med Res. 2019;149(2):295. DOI: 10.4103/ijmr.IJMR_14_18

Prakash V, Mishra PP, Walia PA, Dhawan S, Kumar A. Increasing incidence of multidrug resistant Pseudomonas aeruginosa in inpatients of a tertiary care hospital. Int J Res Med Sci. 2014; 2(4):1302-1306

Abd El-Baky RM, Masoud SM, Mohamed DS, Waly NG, Shafik EA, Mohareb DA et al. Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:323. DOI:10.2147/IDR. S238811

Saderi H, Owlia P. Detection of multidrug resistant (MDR) and extremely drug resistant (XDR) P. aeruginosa isolated from patients in Tehran, Iran. Iranian J Pathol. 2015;10(4):265.

World Health Organization. Global antimicrobial resistance surveillance system (GLASS): The detection and reporting of colistin resistance; 2018. Available:https://apps.who.int/iris/ handle/10665/277175/ Accessed May 31, 2023.

Hayes JF. Fighting back against antimicrobial resistance with comprehensive policy and education: A Narrative review. Antibiotics. 2022;11(5):644.